Archford Capital Strategies LLC Has $1.73 Million Position in Johnson & Johnson (NYSE:JNJ)

Archford Capital Strategies LLC raised its position in Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,731 shares of the company’s stock after buying an additional 64 shares during the period. Archford Capital Strategies LLC’s holdings in Johnson & Johnson were worth $1,727,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Magnolia Capital Management Ltd. grew its holdings in Johnson & Johnson by 0.5% during the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after purchasing an additional 55 shares during the period. Howard Financial Services LTD. grew its holdings in Johnson & Johnson by 2.1% during the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after purchasing an additional 57 shares during the period. American Financial Advisors LLC grew its holdings in Johnson & Johnson by 2.1% during the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after purchasing an additional 57 shares during the period. Taylor & Morgan Wealth Management LLC grew its holdings in Johnson & Johnson by 1.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after purchasing an additional 57 shares during the period. Finally, Kwmg LLC grew its holdings in Johnson & Johnson by 2.6% during the first quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after purchasing an additional 59 shares during the period. 68.59% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $163.28 on Thursday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a fifty day simple moving average of $168.25 and a 200 day simple moving average of $174.16. The stock has a market capitalization of $429.29 billion, a price-to-earnings ratio of 23.77, a PEG ratio of 2.97 and a beta of 0.61. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period in the prior year, the firm posted $2.48 earnings per share. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.7 EPS for the current fiscal year.

Johnson & Johnson announced that its board has initiated a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.77%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on JNJ. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Citigroup reduced their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. UBS Group reduced their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a report on Monday, September 12th. Finally, SVB Leerink reduced their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $189.78.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.